Dr. Bunn on FDA Approval of Brigatinib for Patients With ALK+ NSCLC

Name: Dr. Bunn on FDA Approval of Brigatinib for Patients With ALK+ NSCLC
Uploaded: 2017-04-29T02:00:23.000Z
Description: Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

April 28, 2017

Paul A. Bunn Jr, MD

Video

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).